Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

SwishX raises $2.2 million seed to launch agentic AI for pharma and MedTech

Bengaluru startup targets 100+ enterprise clients and global expansion as it aims to transform pharmaceutical sales, marketing, tenders, and distribution using AI agents

Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial

NEJM study shows strong protection across strains

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

Moderna posts Q1 2026 loss despite revenue surge

Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets

Merck posts mixed Q1 2026 results as blockbuster drugs drive growth

But acquisition charges drag earnings into loss